M

Maat Pharma SA
PAR:MAAT

Watchlist Manager
Maat Pharma SA
PAR:MAAT
Watchlist
Price: 5.08 EUR -0.78% Market Closed
Market Cap: 95.3m EUR
Section:
 

Relative Value

The Relative Value of one MAAT stock under the Base Case scenario is hidden EUR. Compared to the current market price of 5.08 EUR, Maat Pharma SA is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MAAT Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

24.3
P/S
P/S
Price to Sales
24.3
vs History
82
vs Industry
26
Median 3Y
53.2
Median 5Y
58.3
Industry
8.2
Forward
7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-6.1
Median 5Y
-8.1
Industry
24.2
Forward
-1.6
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-7.1
Median 5Y
-7.6
Industry
23
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-6.2
Median 5Y
-7.1
Industry
25.5
More Details
11.5
P/B
P/B
Price to Book Value
11.5
vs History
11
vs Industry
30
Median 3Y
7
Median 5Y
6.2
Industry
3.3
More Details
23.5
EV/S
EV/S
Enterprise Value to Sales
23.5
vs History
82
vs Industry
25
Median 3Y
44.6
Median 5Y
47.7
Industry
8.6
Forward
6.8
More Details
38
EV/GP
EV/GP
Enterprise Value to Gross Profit
38
vs History
82
vs Industry
19
Median 3Y
65.8
Median 5Y
70.8
Industry
10.5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-5.3
Median 5Y
-6.8
Industry
6.1
Forward
-3.6
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-5
Median 5Y
-6.5
Industry
6.6
Forward
-3.6
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-6
Median 5Y
-6.6
Industry
8.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-5.8
Median 5Y
-6.3
Industry
6.8
More Details
3.9
EV/IC
EV/IC
Enterprise Value to IC
3.9
vs History
84
vs Industry
32
Median 3Y
9.6
Median 5Y
11.2
Industry
5.7
More Details

Multiples Across Competitors

MAAT Competitors Multiples
Maat Pharma SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Maat Pharma SA
PAR:MAAT
95.3m EUR 24.3 -3.1 -3.2 -3
IL
Can Fite Biopharma Ltd
TASE:CANF
707T ILS 256 727 549 -17 630 396.1 -17 300 817.5 -17 262 306.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 036 074.3 -161 768.4 -196 438.5 -194 196.9
US
Abbvie Inc
NYSE:ABBV
389B USD 6.5 165.7 16.1 22.8
US
Amgen Inc
NASDAQ:AMGN
175.4B USD 4.9 25 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
150.4B USD 5.2 18.5 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.8B USD 10.1 32.1 23.5 24.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 069.8 -528.2 -575.1 -559.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
83.9B USD 5.9 18.3 17.5 19.9
AU
CSL Ltd
ASX:CSL
84.4B AUD 3.6 18.8 12.7 15.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.5B USD 16.4 1 204.9 162.5 197
P/S Multiple
Revenue Growth P/S to Growth
FR
M
Maat Pharma SA
PAR:MAAT
Average P/S: 26 433 251.8
24.3
87%
0.3
IL
C
Can Fite Biopharma Ltd
TASE:CANF
256 727 549
140%
1 833 768.2
FR
Pharnext SCA
OTC:PNEXF
34 036 074.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.1
10%
1
US
E
Epizyme Inc
F:EPE
2 069.8
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.9
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.4
46%
0.4
P/E Multiple
Earnings Growth PEG
FR
M
Maat Pharma SA
PAR:MAAT
Average P/E: 211.9
Negative Multiple: -3.1 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 630 396.1 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 768.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
165.7
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.5
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.1
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -528.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.3
10%
1.8
AU
CSL Ltd
ASX:CSL
18.8
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 204.9
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
M
Maat Pharma SA
PAR:MAAT
Average EV/EBITDA: 37.6
Negative Multiple: -3.2 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 300 817.5 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 438.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -575.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
11%
1.6
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
162.5
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
M
Maat Pharma SA
PAR:MAAT
Average EV/EBIT: 44.4
Negative Multiple: -3 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 262 306.3 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 196.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.9
13%
1.5
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
197
N/A N/A

See Also

Summary
MAAT intrinsic value, competitors valuation, and company profile.
DCF Valuation
MAAT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MAAT stock valuation using valuation multiples.
Wall Street Estimates
MAAT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MAAT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 308,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.